Regeneron Sees $56 Million Pretax Charge Hitting 3Q Earnings
Provided by
Dow Jones
By Adriano Marchese
Regeneron Pharmaceuticals expects to book a $56 million pretax charge related to collaboration and licensing agreements.
The Westchester County, New York-based biotechnology company said Monday it expects the charge to reduce its income per share by about 43 cents in the third quarter.
According to FactSet, earnings per share we expected rise to $9.55, up from $8.89 a year earlier, while adjusted earnings per share were forecast to be $11.83.
Regeneron said this charge relates to development milestone and up-front payments in connection with collaboration and licensing agreements.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 07, 2024 08:09 ET (12:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Is 16% a Good Return?
-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
New 4-Star Stocks
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
United States